Analysts Set Expectations for Gritstone bio, Inc.’s Q1 2024 Earnings (NASDAQ:GRTS)

Gritstone bio, Inc. (NASDAQ:GRTS) – B. Riley issued their Q1 2024 EPS estimates for shares of Gritstone bio in a report issued on Tuesday, April 16th. B. Riley analyst M. Mamtani anticipates that the company will earn ($0.23) per share for the quarter. The consensus estimate for Gritstone bio’s current full-year earnings is ($0.95) per share. B. Riley also issued estimates for Gritstone bio’s Q4 2024 earnings at ($0.16) EPS and FY2024 earnings at ($0.80) EPS.

Gritstone bio (NASDAQ:GRTS) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company had revenue of $10.38 million for the quarter, compared to analyst estimates of $4.80 million. Gritstone bio had a negative net margin of 847.24% and a negative return on equity of 147.22%.

GRTS has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Gritstone bio in a research report on Wednesday, March 6th. JMP Securities boosted their target price on shares of Gritstone bio from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd.

Gritstone bio Stock Down 1.0 %

Gritstone bio stock opened at $0.74 on Thursday. The business’s 50-day moving average price is $1.99 and its 200 day moving average price is $2.02. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.77. The firm has a market cap of $72.24 million, a price-to-earnings ratio of -0.61 and a beta of 0.38. Gritstone bio has a 52 week low of $0.67 and a 52 week high of $3.33.

Hedge Funds Weigh In On Gritstone bio

Institutional investors and hedge funds have recently modified their holdings of the business. Wexford Capital LP purchased a new position in shares of Gritstone bio during the 4th quarter valued at approximately $26,000. Forum Financial Management LP lifted its position in shares of Gritstone bio by 78.0% in the third quarter. Forum Financial Management LP now owns 17,799 shares of the company’s stock valued at $31,000 after acquiring an additional 7,799 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Gritstone bio by 134.0% in the third quarter. Tower Research Capital LLC TRC now owns 12,325 shares of the company’s stock worth $31,000 after acquiring an additional 7,059 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Gritstone bio during the second quarter worth approximately $33,000. Finally, Alliancebernstein L.P. purchased a new position in Gritstone bio in the 2nd quarter valued at $35,000. Hedge funds and other institutional investors own 48.46% of the company’s stock.

About Gritstone bio

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.